Table 4. Factors associated with mortality after entry to TAHOD.
| No. of | No. of | Rate | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|---|---|
| patients | deaths | (/100 py) | HR | p | HR | p | 95%CI | |
| Total | 7455 | 303 | 1.22 | |||||
| HBsAg testing | ||||||||
| Negative | 5065 | 170 | 1.02 | |||||
| Positive | 591 | 29 | 1.48 | 1.45 | 0.06 | 1.33 | 0.15 | (0.90, 1.98) |
| Not tested | 1799 | 104 | 1.68 | 2.17 | <0.001 | 2.17 | <0.001 | (1.52, 3.10) |
| HCV antibody testing | ||||||||
| Negative | 4421 | 154 | 1.01 | |||||
| Positive | 794 | 46 | 2.53 | 2.22 | <0.001 | 1.81 | 0.004 | (1.21, 2.72) |
| Not tested | 2240 | 103 | 1.33 | 1.34 | 0.02 | 0.86 | 0.43 | (0.60, 1.25) |
| Sex | ||||||||
| Male | 5245 | 241 | 1.36 | |||||
| Female | 2202 | 60 | 0.85 | 0.61 | <0.001 | 0.76 | 0.07 | (0.57, 1.02) |
| Change | 6 | 2 | 10.57 | 7.31 | 0.01 | 7.34 | 0.006 | (1.78, 30.38) |
| Age (years) | ||||||||
| ≦30 | 1879 | 53 | 0.92 | |||||
| 31–50 | 4855 | 171 | 1.03 | 1.15 | 0.38 | 1.07 | 0.66 | (0.79, 1.47) |
| >50 | 721 | 79 | 3.28 | 3.64 | <0.001 | 3.87 | <0.001 | (2.69, 5.57) |
| Mode of infection | ||||||||
| Heterosexual contact | 4920 | 203 | 1.21 | |||||
| Homosexual contact | 1384 | 34 | 0.68 | 0.57 | <0.001 | 0.69 | 0.06 | (0.46, 1.02) |
| Injecting drug use | 602 | 36 | 2.85 | 2.04 | <0.001 | 1.34 | 0.20 | (0.86, 2.08) |
| Other | 549 | 30 | 1.75 | 1.41 | 0.08 | 1.39 | 0.11 | (0.93, 2.07) |
| CDC stage | ||||||||
| CDC A | 3751 | 87 | 0.73 | |||||
| CDC B | 835 | 20 | 0.70 | 0.98 | 0.92 | 0.94 | 0.82 | (0.58, 1.54) |
| CDC C | 2869 | 196 | 1.97 | 2.77 | <0.001 | 2.10 | <0.001 | (1.59, 2.77) |
| Baseline CD4 count | ||||||||
| ≦50 | 1955 | 125 | 2.01 | |||||
| 51–200 | 2558 | 92 | 1.13 | 0.56 | <0.001 | 0.67 | 0.005 | (0.51, 0.89) |
| 201–350 | 1489 | 30 | 0.68 | 0.33 | <0.001 | 0.51 | 0.002 | (0.34, 0.79) |
| 351–500 | 236 | 9 | 1.10 | 0.56 | 0.10 | 0.87 | 0.69 | (0.43, 1.75) |
| ≧501 | 118 | 3 | 0.68 | 0.36 | 0.08 | 0.72 72 | 0.58 | (0.22, 2.33) |
| Not tested | 1099 | 44 | 0.93 | 0.50 | <0.001 | 0.62 | 0.01 | (0.43, 0.91) |
| Baseline HIV viral load | ||||||||
| 40–20000 | 866 | 20 | 0.65 | |||||
| 20001–80000 | 860 | 24 | 0.86 | 1.29 | 0.39 | 1.29 | 0.40 | (0.71, 2.37) |
| 80001–200000 | 833 | 37 | 1.45 | 2.17 | 0.01 | 1.94 | 0.02 | (1.10, 3.42) |
| >200000 | 1127 | 61 | 1.62 | 2.45 | <0.001 | 1.97 | 0.01 | (1.16, 3.35) |
| Not tested | 3769 | 161 | 1.28 | 1.98 | <0.001 | 1.67 | 0.05 | (1.01, 2.77) |
| ARV type | ||||||||
| ARV1 | 6172 | 246 | 1.33 | |||||
| ARV2 | 1152 | 48 | 0.85 | 0.72 | 0.04 | 0.78 | 0.15 | (0.55, 1.10) |
| ARV3 | 131 | 9 | 1.36 | 1.17 | 0.65 | 1.14 | 0.72 | (0.57, 2.29) |
| Prior mono/dual ARV | ||||||||
| No | 6849 | 254 | 1.19 | |||||
| Yes | 606 | 49 | 1.41 | 1.37 | 0.05 | 1.48 | 0.03 | (1.05, 2.08) |
| HIV-1 subtype | ||||||||
| B | 192 | 6 | 0.54 | |||||
| 01AE | 86 | 2 | 0.41 | 0.75 | 0.72 | 0.58 | 0.52 | (0.12, 2.95) |
| 07BC | 2 | 0 | 0 | 0 | 1.00 | 0 | 1.00 | (0, Inf) |
| C | 5 | 0 | 0 | 0 | 0.99 | 0 | 0.99 | (0, Inf) |
| Not tested | 7170 | 295 | 1.27 | 2.08 | 0.08 | 1.71 | 0.99 | (0.74, 3.94) |
ARV1: antiretroviral regimen containing nucleoside reverse transcriptase inhibitor + non-nucleoside reverse transcriptase inhibitor, ARV2: antiretroviral regimen containing nucleoside reverse transcriptase inhibitor + protease inhibitor, ARV3: other antiretroviral regimens